Insilico Medicine completed a Hong Kong initial public offering, raising gross proceeds that capped the company’s multi‑year push to go public. The AI‑driven drug‑discovery firm marketed itself as one of the early movers combining deep learning with medicinal chemistry, and its IPO reflects investor appetite for AI‑enabled biotech despite a cautious funding backdrop. The listing provides Insilico with fresh capital to advance discovery programs and expand partnerships. It also offers a performance benchmark for other computational drug‑discovery companies considering public markets in the region. Market observers will watch how Insilico deploys proceeds into R&D and how its public performance shapes investor sentiment toward AI biotech listings in 2026.